George Papakostas
Professor of Psychiatry at Harvard Medical School; Clinical Investigator at Massachusetts General Hospital
Data updated
Research Footprint
George Papakostas appears in 7 tracked papers (2015–2022), most studied alongside Ketamine, Placebo and Esketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (676 citations).
Frequent co-authors: Gerard Sanacora, Sanjay Mathew and Daniel Iosifescu.
Background & Research
George I. Papakostas, M.D., is a psychiatrist and clinical investigator at Massachusetts General Hospital and Professor of Psychiatry at Harvard Medical School. His research focuses on treatment-resistant major depressive disorder, including rapid-acting antidepressants such as ketamine and esketamine, as well as clinical moderators of treatment response. He has published extensively on depression therapeutics and is active in clinical trial design and implementation.
Key Impact
He is a leading psychiatrist in treatment-resistant depression research and a prominent investigator in ketamine and esketamine studies for rapid-acting antidepressant effects.
Collaboration Network
31 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations George Papakostas is associated with.
Massachusetts General Hospital
hospitalThe Center for the Neuroscience of Psychedelics aims to better understand how psychedelics can be used to improve the treatment of mental illnesses. The core mission of the center is to understand exactly how psychedelics enhance the brain's capacity for change—or neuroplasticity—to optimize current treatments and render the term treatment resistant obsolete.
View stakeholder →Harvard University
Non-ProfitHarvard University hosts multiple psychedelic research initiatives including the Study of Psychedelics in Society and Culture (a $16M program), the MGH Center for the Neuroscience of Psychedelics, and the Harvard Law School POPLAR project addressing psychedelic policy reform. These programs span neuroscience, cultural studies, and legal advocacy to advance scientific and societal understanding of psychedelics.
View stakeholder →